Journal
CLINICAL INFECTIOUS DISEASES
Volume 37, Issue 12, Pages 1693-1698Publisher
UNIV CHICAGO PRESS
DOI: 10.1086/379773
Keywords
-
Categories
Ask authors/readers for more resources
Evolution and transmission of multiply drug- resistant human immunodeficiency virus type 1 ( HIV- 1) may limit therapeutic options as global treatment efforts expand. However, the stability of these mutants in the absence of drug selection pressure is not known. We performed a longitudinal analysis of plasma virus from a person who acquired HIV- 1 that contained multiple reverse transcriptase ( RT) and protease ( PR) mutations. In the absence of therapy, 5 of 12 drug resistance mutations reverted in a stepwise fashion to wild type over the course of 52 weeks. Reversion of the M184V mutation alone did not change viral replicative capacity ( RC), but it led to enhanced resistance to zidovudine and tenofovir. However, reversions of a second RT mutation and 3 PR mutations were associated with an increase in viral RC, and this was temporally correlated with a marked decrease in CD4 cell number. This study demonstrates the gradual stepwise back- mutation of certain drug resistance mutations in vivo in the absence of ongoing drug selection pressure. Moreover, it suggests that, despite initially impaired viral fitness, a transmitted HIV- 1 isolate with multiple drug resistance mutations can evolve to develop increased RC and significant pathogenicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available